Sugi Predict

Sugi Predict / Compounds / SCHEMBL6597896

SCHEMBL6597896

SCHEMBL6597896

CC(N)Cc1cc(C#N)c2c(c1)CCN2CCCOC(=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA1D P25100 12/20 0.40
▸ ADRA1A P35348 12/20 0.40
▸ ADRA1B P35368 12/20 0.40
▸ SCN1A P35498 1/20 0.39
▸ SCN2A Q99250 1/20 0.39
▸ SCN3A Q9NY46 1/20 0.39
▸ DRD3 P35462 2/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ DRD1 P21728 1/20 0.38
▸ DRD4 P21917 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ HTR1D P28221 1/20 0.38
▸ HTR1B P28222 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1822655 1.00 ADRA1D (0.40) ADRA1DADRA1AADRA1BSCN1ASCN2A
SCHEMBL16422049 1.00 ADRA1D (0.40) ADRA1DADRA1AADRA1BSCN1ASCN2A
Cadaverine Tartrate SCHEMBL13730985 0.96 ADRA1D (0.38) ADRA1DADRA1AADRA1BSCN1ASCN2A
Cadaverine Tartrate SCHEMBL28639321 0.96 ADRA1D (0.38) ADRA1DADRA1AADRA1BSCN1ASCN2A
Tartaric Acid SCHEMBL29358996 0.96 ADRA1D (0.38) ADRA1DADRA1AADRA1BSCN1ASCN2A
Cadaverine Tartrate SCHEMBL6595413 0.96 ADRA1D (0.38) ADRA1DADRA1AADRA1BSCN1ASCN2A
Cadaverine Tartrate SCHEMBL29120481 0.96 ADRA1D (0.38) ADRA1DADRA1AADRA1BSCN1ASCN2A
SCHEMBL13729910 0.91 ADRA1D (0.40) ADRA1DADRA1AADRA1BDRD3ADRB2
SCHEMBL17516024 0.91 ADRA1D (0.39) ADRA1DADRA1AADRA1BSCN1ASCN2A
SCHEMBL15694648 0.90 ADRA1D (0.37) ADRA1DADRA1AADRA1BDRD3ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114751852-B Preparation method of silodosin key intermediate 山西库邦生物医药科技有限公司 2023-09-15 — — CN claimed
CN-114751852-A Preparation method of key intermediate of silodosin 山西库邦生物医药科技有限公司 2022-07-15 — — CN claimed
CN-110452149-B Preparation method of indoline compound, indoline compound and application 北京鑫开元医药科技有限公司 2021-11-02 — — CN claimed
WO-2012147107-A2 NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION MSN LABORATORIES LIMITED (IN) 2012-11-01 — — WO claimed
CN-114751852-B Preparation method of silodosin key intermediate 山西库邦生物医药科技有限公司 2023-09-15 — — CN disclosed
CN-114751852-A Preparation method of key intermediate of silodosin 山西库邦生物医药科技有限公司 2022-07-15 — — CN disclosed
CN-110452149-B Preparation method of indoline compound, indoline compound and application 北京鑫开元医药科技有限公司 2021-11-02 — — CN disclosed
US-10421719-B2 Maleic acid salt of a silodosin intermediate URQUIMA S.A. (ES) 2019-09-24 — — US disclosed
US-10377710-B2 Process for the preparation of considerably pure Silodosin MANKIND PHARMA LTD. (IN) 2019-08-13 — — US disclosed
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2019-03-26 — — US disclosed
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin MANKIND PHARMA LTD. (IN) 2019-03-26 — — US disclosed
CN-108929259-A A method of preparing Silodosin intermediate 四川青木制药有限公司 2018-12-04 — — CN disclosed
WO-2012147107-A2 NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION MSN LABORATORIES LIMITED (IN) 2012-11-01 — — WO disclosed
WO-2012131710-A2 NOVEL PROCESS FOR THE SYNTHESIS OF INDOLINE DERIVATIVES PANACEA BIOTEC LTD (IN) 2012-10-04 — — WO disclosed
WO-2011124704-A1 PROCESS FOR PREPARING AN INTERMEDIATE FOR SILODOSIN RATIOPHARM GMBH (DE) 2011-10-13 — — WO disclosed
US-20040235932-A1 Ophthalmic pharmaceutical compositions Outdoor Wireless Networks LLC 2004-11-25 — — US disclosed
EP-1415666-A1 MEDICINAL COMPOSITIONS FOR OPTHALMIC USE Kissei Pharmaceutical Co., Ltd. (JP) 2004-05-06 — — EP disclosed
EP-1057813-B1 INDOLE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME KISSEI PHARMACEUTICAL (JP) 2004-04-21 — — EP disclosed
US-6310086-B1 PREVENTION OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2001-10-30 — — US disclosed
EP-1057813-A1 INDOLE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2000-12-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10239833-B2 Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin ADRA1D, ADRB1, ADRA1A ADRA1D 1/4885ADRA1A 3/4885ADRA1B 5/4885
US-10421719-B2 Maleic acid salt of a silodosin intermediate MEP1A, PTMA, MSMO1 ADRA1D 549/4885ADRA1A 670/4885ADRA1B 1114/4885
US-10377710-B2 Process for the preparation of considerably pure Silodosin CYP51A1, LSS, SRI ADRA1D 378/4885ADRA1A 646/4885ADRA1B 557/4885
US-20040235932-A1 Ophthalmic pharmaceutical compositions ADRA1A, ADORA1, ADRA1D ADRA1D 3/4885ADRA1A 1/4885ADRA1B 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.